

# WOAH Collaborative Centre Reports Activities 2025

This report has been submitted: 14 janvier 2026 16:45

## CENTRE INFORMATION

*Title of WOA Collaborating Centre	Quality Control of Veterinary Vaccines in the Middle East
*Address of WOA Collaborating Centre	Central Laboratory for Evaluation of Veterinary Biologics (CLEVB)
*Tel:	+20223422505
*E-mail address:	clevb.info@clevb-arc.com
Website:	www.clevb-arc.com
*Name Director of Institute (Responsible Official):	Prof. Dr. Samir Abdel Moez Nassef
*Name (including Title and Position) of Head of the Collaborating Centre (WOAH Contact Point):	Prof. Dr. Samir Abdel Moez Nassef, Director of CLEVB
*Name of the writer:	Prof. Dr. Samir Abdel Moez Nassef

## TOR 1 AND 2: SERVICES PROVIDED

1. Activities as a centre of research, expertise, standardisation and dissemination of techniques within the remit of the mandate given by WOA

Category	Title of activity	Scope
Training, capacity building (true)	Training about Veterinary Biologics Evaluation	* Veterinarians of post graduated, and from different Research Institute and Centers * Students of Faculties of Veterinary Medicine, Agriculture and Science * Veterinarians from Different Middle East Countries
Veterinary medicinal products (true)	Evaluation of Veterinary Biologics	Evaluation of different veterinary biologics e.g. Vaccines, Serum, Antigens and diagnostics
Vaccines (true)	Evaluation of Veterinary Biologics	Evaluation of all types of veterinary vaccines for poultry, large animals, pet animals and aquaculture vaccines

## TOR 3: HARMONISATION OF STANDARDS

2. Proposal or development of any procedure that will facilitate harmonisation of international regulations applicable to the main focus area for which you were designated

Proposal title	Scope/Content	Applicable Area

3. In exercising your activities, have you identified any regulatory research needs\* relevant for WOA?

Yes

### Research need 1

**Please type the Research need:** Risk analysis for the impact of presence of bacterial contamination suspected to be pathogenic for both poultry and human beings (such as enterococcus faecalis), in the live attenuated viral poultry vaccines that applied in drinking water

**Relevance for WOAHP Other, Sterility Tests for live attenuated viral poultry vaccines,**

**Relevance for the Code or Manual Manual,**

**Field Vaccines,**

**Animal Category Terrestrial,**

**Disease:**

Infectious bursal disease (Gumboro disease)

Newcastle disease

**Kind of disease (Zoonosis, Transboundary diseases) Transboundary diseases,**

**If any, please specify relevance for Codes or Manual, chapter and title**

(e.g. Terrestrial Manual Chapter 2.3.5 - Minimum requirements for aseptic production in vaccine manufacture)

*Answer:* Terrestrial Manual Chapter 1.1.9. Tests for sterility and freedom from contamination of biological materials intended for veterinary use

**Notes:**

*Answer:*

4. Did your Collaborating Centre maintain a network with other WOAHP Collaborating Centres (CC), Reference Laboratories (RL), or organisations designated for the same specialty, to coordinate scientific and technical studies?

Yes

Name of WOAHP CC/RL/other organisation(s)	Location	Region of networking Centre	Purpose
Faculty of Veterinary Medicine, Cairo University	Egypt	Oriente Medio	Training, Master and PhD Supervision, Research Projects, Experience exchange
General Organization OF Veterinary Services (GOVS)	Egypt	Oriente Medio	License of Veterinary Biologics GOVS is liaison the between CLEVB and the vaccines manufacture/importers
FAO	Egypt	Oriente Medio	FAO supports CLEVB with the resources that facilitate the vaccine evaluation processes
GD Laboratories	Netherlands	Europa	Proficiency Test
FLI Laboratories	Germany	Europa	Internships, Biosafety and biosecurity, Diagnostics (There is a Memorandum of Cooperation)
Istituto Zooprofilattico Sperimentale	Italy	Europa	Proficiency Test for Avian Influenza vaccine and viruses including H5 and H9; besides Newcastle Disease vaccine and viruses

## TOR 4 AND 5: NETWORKING AND COLLABORATION

5. Did your Collaborating Centre maintain a network with other WOAHP Collaborating Centres, Reference laboratories, or organisations in other disciplines, to coordinate scientific and technical studies?

Yes

		Region of	
--	--	-----------	--

--

Name of WOAHC/RL/other organisation(s)	Location	networking Centre	Purpose
Animal Health Research Institute (AHRI)	Egypt	Middle East	Training, Interlab comparison, Research Projects, Experience exchange AHRI provides our lab with field strains of challenge viruses
GIBACHT	Germany	Europe	Training on biosafety and biosecurity
CDC	USA	Americas	Online training on biorisk management system
Sandia National Labs	USA	Americas	Training on Biosafety and biosecurity
Academy of Scientific Research and Technology (ASRT)	Egypt	Middle East	Research Projects

## TOR 6: EXPERT CONSULTANTS

6. Did your Collaborating Centre place expert consultants at the disposal of WOAHC?

Yes

Name of expert	Kind of consultancy	Subject
Prof. Dr. Afaf A. Khedr	Alternative to antimicrobial resistance (AMR)	Write a reflection paper on Autogenous vaccines

## TOR 7: SCIENTIFIC AND TECHNICAL TRAINING

7. Did your Collaborating Centre provide advice/services to requests from Members in your main focus area?

Yes

*CLEVB received Lumpy skin disease vaccine samples from Klybeck Life Science Factory, Saudi Arabia, for evaluation*

8. Did your Collaborating Centre provide scientific and technical training, within the remit of the mandate given by WOAHC, to personnel from WOAHC Members?

Yes

a) Technical visit : 0

b) Seminars : 52

c) Hands-on training courses: 0

d) Internships (>1 month) : 0

Type of technical training provided (a, b, c or d)	Content	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
B	"Foot and Mouth Disease Virus (FMDV) and Vaccines"	Egypt	52

## TOR 8: SCIENTIFIC MEETINGS

9. Did your Collaborating Centre organise or participate in the organisation of scientific meetings related to your main focus area on behalf of WOAHC?

Yes

National/International	Title of event	Co-organiser	Date	Location	No. Participants
Internationally	23rd WVPA Congress	Malaysian VPA	2025-10-06	Malaysia	1200
Internationally	WOAH Meeting for Middle East Countries	Cyprus Governmental Veterinary Services	2025-11-24	Cyprus	35

## TOR 9: DATA AND INFORMATION DISSEMINATION

10. Publication and dissemination of any information within the remit of the mandate given by WOA that may be useful to Members of WOA

a) Articles published in peer-reviewed journals:

0

b) International conferences:

4

1. *Emergence of a hyper virulent Newcastle Disease Virus genotype VII in Egypt: Characterization and Pathogenicity shift*
2. *Inactivated Newcastle Disease Virus Vaccine efficacy in SPF chicks against hyper virulent genotype VII isolates: Comparative analysis of historical and homologous strains with and without immunostimulants*
3. *Protection against HPAI-H5N1 early challenge in commercial broilers with maternal immunity: Prime boost vs. single vaccination of a trivalent H5 inactivated Vaccine*
4. *Efficacy of a commercial v HVT + IBD + H5 vaccine in commercial broilers when challenged with field IBD Egyptian reassortant virus*

c) National conferences:

0

d) Other (Provide website address or link to appropriate information):

11. What have you done in the past year to advance your area of focus, e.g. updated technology?

1. *Using of RT-PCR as an alternative method for qualification of live attenuated viral (RNA) vaccines.*
2. *Using of Lab Animals such as Guinea pigs as a model for evaluation of some large animal vaccines.*
3. *Using of lateral flow technique for evaluation of some pet animal vaccines*

12. Additional comments regarding your report: